Stephan Moll

Stephan Moll

Freiburg University, Germany

MD

1979-1986

Medical School

Hammersmith Hospital and the Institute of Neurology Queen’s Square , London, Great Britain

1985-1986

Last year of Medical School (visiting student)

University of Freiburg, Institute of Pharmacology

1983-1985

Pharmacology (MD thesis)

University of  Aachen, Institute of Pathology

Postgraduate work

1987-1989

pathology

Duke University Medical Center, Dept. of Medicine

internship/
residency

1989-1992

Internal Medicine

Duke University Medical Center, Dept. of Medicine, Division of Hematology-Oncology

fellowship

1993-1994

hematology/oncology

University of North Carolina at Chapel Hill

fellowship

1994-1995

clinical coagulation

Duke University Medical Center, Dept. of Medicine, Division of Hematology-Oncology

fellowship

1995-1996

hematology/oncology

RESEARCH AND PROFESSIONAL EXPERIENCE:

1997-1999             Position in clinical hemostaseology and cardiology and director of the clinical coagulation and chemistry laboratory at Humboldt University Charité, Berlin, Germany.
1999-2006             Assistant professor in the Department of Medicine, Division of Hematology-Oncology, University of North Carolina School of Medicine, Chapel Hill, NC.
2006 to present      Associate professor in the Department of Medicine, Division of Hematology-Oncology, University of North Carolina School of Medicine, Chapel Hill, NC.

HONORS AND AWARDS

  • University of North Carolina “Department of Medicine Recognition Award – recognizing dedication to and support of teaching”

2007     University of North Carolina “Department of Obstetrics and Gynecology Outstanding Consultant Award – in appreciation of dedication to the care of our patients and education of our physicians”.

NATIONAL AND INTERNATIONALMEDICAL ORGANIZATIONS AND SOCIETIES

  • Chairman of the Medical and Scientific Advisory Board of the non-profit organization “National Alliance for Thrombosis and Thrombophilia”
  • Member of American Society of Hematology
  • Member of International Society for Thrombosis and Haemostasis

SELECTED PUBLICATIONS

  1. Moll S, White G: Treatment of the hemophilias. Current Opinion Hematol 1995;2:386-394.
  2. Moll S, McCloud M, Ortel TL: Lupus Anticoagulant and Subdural Hematoma. Stroke 1997;28:646-648.
  3. Moll S, Ortel T: Monitoring Warfarin Therapy in Patients with Lupus Anticoagulants. Ann Intern Med,1997;127:177-185.
  4. Moll S. Homocysteine and Mortality in Coronary Artery Disease.  N Engl J Med 1997;337:1631-1632.
  5. Moll S, Rico-Lazarowski A, White GC: Giant Platelet Disorder in a Patient with Type 2B von Willebrand's Disease. Am J Hematol 1998, 57:62-67.
  6. Moll S, Ortel TL: Monitoring Warfarin Therapy in Patients with Lupus Anticoagulants. Ann Intern Med, 1998,128:504-505.
  7. Ortel TL, Moll S: Warfarin Therapy in Patients with Lupus Anticoagulants. Br J Haematol,1998:101:390-391.
  8. Moll S, Ortel TL: Diagnosis of Pulmonary Embolism. N Engl J Med 1998;339:1084.
  9. Moll S: Eptifibatide in Acute Coronary Syndromes.  N Engl J Med 1999;340:60-61.
  10. Moll S., Poepping I, Hauck S, Gulba D, Dietz R:  Pseudothrombocytopenia after Abciximab (ReoPro®) Treatment. Circulation 1999, 100:1460.
  11. Moll S, Escobar M: Prothrombin and Factor V Mutations in Patients with History of Thrombosis During Pregnancy and Puerperium. N Engl J Med 2000;342:1996.
  12. Moll S.: A Low Molecular Weight Heparin Preparation Contraindicated in Pregnancy. Am J Obstetr Gynecol. 2001;184:1046.
  13. Moll S, Ortel TL: Antiphospholipid antibodies. Arch Intern Med 2002;162:1783-4.
  14. Moll S, Roberts HR: Overview of anticoagulant drugs for the future. Semin in Hematol 2002;39:145-57.
  15. Rick ME, Moll S, Taylor MA, Krizek DM, White II GC, Aronson DL: Clinical use of a rapid collagen binding assay for von Willebrand factor cleaving protease in patients with thrombotic thrombocytopenic purpura. Thromb Haemost. 2002;88:598-604.
  16. Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby C, Deitcher SR, Cushman M, Moll S, Kessler, CM, Elliott G, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, Bounameaux H, Glynn RJ: Long-term low-intensity warfarin for the prevention of recurrent venous thromboembolism: a randomized, double-blind, placebo-controlled trial. N Engl J Med 2003:348:1425-34.
  17. Moll S: Use of combined CT venography and CT pulmonary arteriography. J Thromb Haemost. 2003;1:637-9.
  18. Hellman EA, Leslie N, Moll S: Knowledge and Information Satisfaction of Individuals with Factor V Leiden Mutation. J Thromb Haemost. 2003;1:2335-9.
  19. Varga EZ, Moll S: Cardiology Patient Page: Prothrombin 20210 mutation (factor II mutation). Circulation 2004;110:e15-e18. .
  20. Moll S, Lindley C, Pescatore S, Morrison D, Tsuruta K, Mohri M, Serada M, Sata M, Shimizu H, Yamada K, White GC: Phase I study of a novel human soluble thrombomodulin, ART-123. J Thromb Haemost 2004;2:1745-51.
  21. Moll S: Warfarin-induced Skin Necrosis. Images in Hematology. Br J Haematol  2004;126:628.
  22. Varga EZ, Sturm AC, Misita CP, Moll S: Cardiology Patient Page: Homocysteine and MTHFR Mutations: Relation to Thrombosis and Coronary Artery Disease. Circulation 2005;111:e289-e293.
  23. Misita CP, Moll S: Cardiology Patient Page: Antiphospholipid Antibodies. Circulation 2005;112:e39-44.
  24. Ohman EM, Granger CB, Rice L, Abrams CS, Becker RC, Berger PB, Kleiman NS, Moliterno D, Moll S, Rodgers JE, Steinhubl SS, Tapson VF, Sinnaeve P, Anstrom KJ: Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: a registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease. The Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry steering committee. J Thromb Thrombolysis 2005;19:11-9.
  25. Moll S: Thrombophilias – Practical implications and testing caveats. J Thromb Thrombolysis 2006;21:7-15.
  26. Cushman M, Glynn RJ, Goldhaber SZ, Moll S, Bauer KA, Deitcher S, Shrivastava S, Ridker PM. Hormonal factors and risk of recurrent venous thrombosis: the prevention of recurrent venous thromboembolism trial. J Thromb Haemost. 2006 Jul 26;4:2199-2203.
  27. Shrivastava S, Ridker PM, Glynn RJ, Goldhaber SZ, Moll S, Bounameaux H, Bauer KA, Kessler CM, Cushman M. D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost. 2006 Jun;4(6):1208-14.
  28. Moll S, Kenyon P, Bertoli L, De Maio J, Homesley H, Deitcher SR. Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devices. J Clin Oncol. 2006 Jul 1;24(19):3056-60.
  29. Ford SK, Misita CP, Bryant-Shilliday B, Malone R, Moore C, Moll S. Prospective study of supplemental vitamin K therapy in patients on oral anticoagulants with unstable international normalized ratios. J Thromb Thrombolysis. 2006 Aug;24(1):23-7. Epub 2007 Feb 24.
  30. Dowling NF, Ortel TL, Beckman MG, Manco-Johnson M, Phillip CS, Moll S, Heit JA, Penner J, Bockenstedt P, Andersen J, Crudder S, James AH, Zimmerman S, Michaels LA, Kulkarni, R, Hassell K, Pipe S. The CDC Hemostasis and Thrombosis Centers (HTC) Pilot Sites Program. J Thromb Thrombolysis. 2007 Feb;23(1):1-7.
  31. Oliveira GB, Crespo EM, Becker RC, Honeycutt EF, Abrams CS, Anstrom KJ, Berger PB, Davidson-Ray LD, Eisenstein EL, Kleiman NS, Moliterno DJ, Moll S, Rice L, Rodgers JE, Steinhubl SR, Tapson VF, Ohman EM, Granger CB; for the Complications After Thrombocytopenia Caused by Heparin (CATCH) Registry Investigators. Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med. 2008 Jan 14;168(1):94-102.

GRANT SUPPORT
ACTIVE

The purpose of this multi-institutional grant is to study rare thrombophilic disorders, such as heparin-induced  thrombocytosis, antiphospholipid antibody syndrome, and thrombotic storm, with special focus on underlying genetic determinants of the development of these disorders.

RECOVER trial
Boehringer-Ingelheim-sponsored multicenter trial entitled “Efficacy and safety of oral Dabigatran compared to warfarin for 6 month treatment for acute symptomatic venous thromboembolism. Phase 3 trial”.
      Moll S: Site-principal investigator at UNC.
      Start date 02/01/07
Effort: 3 %
This is a multicenter, randomized, double-blind blind trial to investigate efficacy and safety of the oral anticoagulant Dabigatran in the secondary prevention of venous thromboembolism.

EINSTEIN VTE Trial
“Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis and/or pulmonary embolism (the Einstein-VTE treatment study)“
7/10/07 – 7/9/10. 
$49,486.  Effort 3%. 
This is a multicenter, randomized, open-label, assessor-blind, event-driven, non-inferiority program for efficacy with a study treatment duration of 3, 6, or 12 months. The program consists of two independent evaluations: 1) one in patients with confirmed acute symptomatic DVT without symptomatic PE (Einstein-DVT), and 2) one in patients with confirmed acute symptomatic PE with or without symptomatic DVT (Einstein-PE). In patients with symptomatic PE, a dose confirmation phase will be implemented.

EINSTEIN Extension Trial
“Once-daily oral direct factor Xa inhibitor rivaroxaban in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism (the Einstein-Extension study)“
7/10/07 – 7/9/10.
$53,798. Effort 3%.
This is a multicenter, randomized, double-blind, placebo-controlled, event-driven, superiority study for efficacy.  The primary efficacy objective is to evaluate whether rivaroxaban is superior to placebo in the long-term prevention of recurrent symptomatic venous thromboembolism (VTE) in patients with symptomatic deep-vein thrombosis (DVT) or pulmonary embolism (PE) who completed 6 or 12 months of treatment with vitamin K antagonist (VKA) or rivaroxaban.

Thrombosis and Hemostasis Centers Research and Prevention Network
CDC grant (Number: 1 U01 DD000292-01).  Principal Investigator: Moll, Stephan. 7/15/2007-6/30/2012:
$171233. Effort 20%
The purpose of this grant is to create a Comprehensive Thrombosis Clinic structure that (a) allows epidemiologic research to be done through use of a clinic patient registry, (b) enables the addition of a biologic sample repository to allow basic research questions to be asked off the Registry, (c) uses the Registry as an identification point of eligible patients for prospective studies on thrombosis and thrombophilia, (d) creates patient support group structures within North Carolina and (e) educates the public, patients and health care providers about thrombosis.

Salary support through a Centers for Disease Control Cooperative Agreement (U27 DD00326; PI: Alan Brownstein).
Effort 5%

INACTIVE
REMEDY trial
Boehringer-Ingelheim-sponsored multicenter trial entitled “A phase III, randomized, double-blind, parallel-group, active controlled study to evaluate the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for the secondary prevention of venous thromboembolism. RE-MEDY.”
Moll S: Site-principal investigator at UNC.   
Start date 02/01/06
Effort: 3 %

AR02248 (Roubey)                        
09/30/00 – 09/29/05       5%
      NIAMS/NIH                                 
Antiphospholipid Syndrome Collaborative Registry
The purpose of this contract is to establish a national registry for the Antiphospholipid Syndrome and related conditions.  The registry will collect and update clinical, demographic, and laboratory data on patients with APS, asymptomatic patients with antiphospholipid antibodies, and certain individuals with serological and/or clinical features that fall within an expanded concept of APS.  The registry will also serve as a repository of sera, plasma, and DNA.
Overlap: none

HA006 (Moll)                                
09/12/05 – 09/12/06       2%
       Nuvelo Pharmaceuticals                            
A Phase III, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Alfimeprase for Restoring Function in Occluded Central Venous Catheters
The purpose of this multicenter, pharmaceutical-company funded study is to study the efficacy of the new thrombolytic receombinant agent Alfimeparse in opening occluded central venous catheters.
      Overlap: none

Sonoma II trial
Nuvelo Pharmaceuticals-sponsored multicenter trial entitled “Phase 3 trial of new thrombolytic agent Alfimeprase versus placebo in patients with occluded central venous catheter”.
Moll S: Site-principal investigator at UNC and international steering committee member.
09/12/05 – 09/12/06
effort 5%

Van Gogh DVT 
Sanofi Pharmaceuticals-sponsored trial. Study EFC3491/64717; multicenter trial entitled “Randomized trial of a new anti-Xa anticoagulant, Idraparinux, with standard therapy vitamin K antagonists in patients with acute deep vein thrombosis”. Unpublished.
Moll S: Site-principal investigator at UNC.
3/01/04 - 2/28/05
13% effort (to a max of 10% of actual salary)

Van Gogh PE 
Organon Pharmaceuticals-sponsored multicenter trial, 112-64714 (286), entitled “Randomized trial of a new anti-Xa anticoagulant, Idraparinux, with standard therapy vitamin K antagonists in patients with acute pulmonary embolism with or without deep vein thrombosis”. Unpublished.
Moll S: Site-principal investigator at UNC.
10/01/03 - 09/30/04
12.5% effort

SONOMA I trial
Nuvelo Pharmaceuticals multicenter trial (protocol Number: HA003), entitled “Phase I study of a new   thrombolytic agent (Alfimeprase) in occluded central venous catheters”. Publication: Deitcher SR et al. Blood. 2004 Nov 16;104(11):490a.
      Moll S: Site-principal investigator at UNC.
      04/0 1/03 - 03/30/05
      11% effort

CLOT study
Pharmacia-Upjohn multicenter trial, entitled “A randomized trial of long term dalteparin low molecular weight heparin (LMWH) versus oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism (VTE)”. Publication: Lee AYY et al. N Engl J Med. 2003 Jul 10;349(2):146-53.
Moll S: Site-principal investigator at UNC.
4/12/00 - 4/6/02
5 % effort              

      THRIVE V trial
Astra-Zeneca-sponsored multicenter trial, entitled “A randomized, double-blind trial of standard therapy anticoagulation (LMWH followed by 6 months of warfarin) with the oral anticoagulant Ximelagatran for 6 months in patients with acute venous thromboembolism”. Publication: Fiessinger JN et al. JAMA. 2005 Feb 9;293(6):736-9.
Moll S: Site-principal investigator at UNC.
      8/17/00 - 12/4/02
      5 % effort

Building Interdisciplinary Research Careers in Women’s Health (BIRCWH)
      K12 NIH grant. HD 01441-01 (Principal Investigator: Orringer EP).
Scholar on grant: Moll S                        
7/11/01 - 1/31/03          
      75% effort

PREVENT trial
      NHLBI grant: RO1-HL57951-01A1 (Principal investigator Ridker P).
Muticenter trial, entitled “Long-term low-intensity warfarin for the prevention of recurrent venous     thromboembolism: a randomized, double-blind, placebo-controlled trial”.    Publication: Ridker PM et al. N Engl J Med. 2003 Apr 10;348(15):1425-34.
Moll S: Site-principal investigator at UNC
10/01/99 - 5/1/04
0% effort